CA2227871A1 - Apport de polynucleotides dans les muqueuses - Google Patents
Apport de polynucleotides dans les muqueuses Download PDFInfo
- Publication number
- CA2227871A1 CA2227871A1 CA002227871A CA2227871A CA2227871A1 CA 2227871 A1 CA2227871 A1 CA 2227871A1 CA 002227871 A CA002227871 A CA 002227871A CA 2227871 A CA2227871 A CA 2227871A CA 2227871 A1 CA2227871 A1 CA 2227871A1
- Authority
- CA
- Canada
- Prior art keywords
- polynucleotide
- composition
- animal
- binding protein
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
On décrit une composition d'apport d'un polynucléotide à des cellules de muqueuses, des cellules neurales ou autres, laquelle comprend une association d'une protéine de liaison de GM1 et d'un polynucléotide. On décrit également un procédé de modulation de l'immunité, consistant à administrer ladite composition à un animal et à faire s'exprimer le polynucléotide dans l'animal, ce qui permet à ce dernier de produire une réponse immune au produit du polynucléotide. On décrit encore une méthode de thérapie génique consistant à administrer à un animal une protéine de liaison du GM1 ainsi qu'un polynucléotide fonctionnel et à faire s'exprimer le polynucléotide dans l'animal, la fonction du polynucléotide exerçant ainsi sur l'animal un effet thérapeutique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US152795P | 1995-07-26 | 1995-07-26 | |
US60/001,527 | 1995-07-26 | ||
PCT/US1996/012041 WO1997005267A2 (fr) | 1995-07-26 | 1996-07-19 | Apport de polynucleotides dans les muqueuses |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2227871A1 true CA2227871A1 (fr) | 1997-02-13 |
Family
ID=21696500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002227871A Abandoned CA2227871A1 (fr) | 1995-07-26 | 1996-07-19 | Apport de polynucleotides dans les muqueuses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0840796A2 (fr) |
JP (1) | JPH11510164A (fr) |
AU (1) | AU6505796A (fr) |
CA (1) | CA2227871A1 (fr) |
WO (1) | WO1997005267A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6553398A (en) * | 1997-03-12 | 1998-09-29 | Hybridon, Inc. | Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides |
GB9713122D0 (en) * | 1997-06-20 | 1997-08-27 | Chiron Spa | Novel method of DNA transfer into cells |
BR9914160A (pt) * | 1998-09-30 | 2001-06-26 | American Cyanamid Co | Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante |
US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
US7041296B1 (en) * | 1999-11-12 | 2006-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of treating inflammatory bowel disease using cholera toxin B subunit |
CN1541111A (zh) | 2001-06-07 | 2004-10-27 | ���Ͽع�����˾ | 作为佐剂的霍乱全毒素的突变形式 |
EP1404368B1 (fr) | 2001-06-07 | 2009-12-09 | Wyeth Holdings Corporation | Formes mutantes de l'holotoxine du cholera en tant qu'adjuvant |
CN101143221A (zh) * | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
EP2318832B1 (fr) | 2008-07-15 | 2013-10-09 | Academia Sinica | Matrices de glycane sur des lames de verre revêtues d' aluminium de type ptfe et procédés associés |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
EP3129767B1 (fr) | 2014-03-27 | 2021-09-01 | Academia Sinica | Composés de marquage réactifs et leurs utilisations |
KR20170005142A (ko) | 2014-05-27 | 2017-01-11 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
EP3149037A4 (fr) | 2014-05-27 | 2018-01-10 | Academia Sinica | Glycoanticorps anti-her2 et leurs utilisations |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
EP3149036A4 (fr) | 2014-05-27 | 2017-12-27 | Academia Sinica | Glycoanticorps anti-cd20 et leurs utilisations |
JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗TNFα糖操作抗体群およびその使用 |
TWI745275B (zh) | 2014-09-08 | 2021-11-11 | 中央研究院 | 使用醣脂激活人類iNKT細胞 |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
CA3016170A1 (fr) | 2016-03-08 | 2017-09-14 | Academia Sinica | Procedes de synthese modulaire de n-glycanes et de puces a n-glycanes |
CA3034057A1 (fr) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Anticorps, fragments de liaison, et procedes d'utilisation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
JPS63258493A (ja) * | 1987-04-15 | 1988-10-25 | Mitsui Toatsu Chem Inc | 抗ガングリオシドgm↓1単クロ−ン性抗体、これを産生する細胞及びこれから成る試薬 |
PT92511A (pt) * | 1988-12-07 | 1990-06-29 | Univ Leicester | Processo de preparacao de um hospedeiro transformado e de proteinas de fusao da subunidade b de toxina labil ao calor |
EP0418626B1 (fr) * | 1989-09-08 | 1993-12-29 | Takeda Chemical Industries, Ltd. | Protéines fusionnées, et leur production |
IL96475A0 (en) * | 1989-11-29 | 1991-08-16 | Innovative Tech Center | Chimeric proteins |
US5433946A (en) * | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5972336A (en) * | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
GB2292887B (en) * | 1993-04-16 | 1997-05-07 | Univ Portsmouth Enterprise | Drug delivery system |
US5681571A (en) * | 1993-10-08 | 1997-10-28 | Duotol Ab | Immunological tolerance-inducing agent |
-
1996
- 1996-07-19 EP EP96924664A patent/EP0840796A2/fr not_active Withdrawn
- 1996-07-19 JP JP9507664A patent/JPH11510164A/ja active Pending
- 1996-07-19 AU AU65057/96A patent/AU6505796A/en not_active Abandoned
- 1996-07-19 CA CA002227871A patent/CA2227871A1/fr not_active Abandoned
- 1996-07-19 WO PCT/US1996/012041 patent/WO1997005267A2/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1997005267A3 (fr) | 1997-04-24 |
AU6505796A (en) | 1997-02-26 |
JPH11510164A (ja) | 1999-09-07 |
EP0840796A2 (fr) | 1998-05-13 |
WO1997005267A2 (fr) | 1997-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2227871A1 (fr) | Apport de polynucleotides dans les muqueuses | |
US5830877A (en) | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory | |
US5985847A (en) | Devices for administration of naked polynucleotides which encode biologically active peptides | |
CA2169635C (fr) | Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs | |
CA2425745C (fr) | Expression des sequences polynocleotides exogenes chez un vertebre | |
US20170044540A1 (en) | Sarna compositions and methods of use | |
Bartlett et al. | Lipopeptide-based oral vaccine against hookworm infection | |
US20240035026A9 (en) | Hnf4a sarna compositions and methods of use | |
JPH06509563A (ja) | 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子 | |
US20060240091A1 (en) | Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof | |
Nakamura et al. | Lipid nanoparticles fuse with cell membranes of immune cells at low temperatures leading to the loss of transfection activity | |
JP2003530360A (ja) | 薬剤送達のためのペプチド複合体 | |
CA2355334A1 (fr) | Preparations pharmaceutiques et methodes visant a inhiber la croissance de tumeurs | |
US20160022767A1 (en) | Protein particles comprising disulfide crosslinkers and uses | |
JP2001526181A (ja) | 遺伝子輸送体であるグラフト共重合体 | |
US7592320B2 (en) | Cancer gene therapy based on translational control of a suicide gene | |
Denes et al. | Protection of NOD mice from type 1 diabetes after oral inoculation with vaccinia viruses expressing adjuvanted islet autoantigens | |
US20210102204A1 (en) | Sirt1-sarna compositions and methods of use | |
US8679780B2 (en) | Method of reducing immunological tolerance to malignancy | |
AU3789099A (en) | Myelin basic protein peptides and uses thereof | |
Yong et al. | Stability analysis of recombinant human TFF2 and its therapeutic effect on burn-induced gastric injury in mice | |
KR20090092536A (ko) | 유전자 전달 효율이 개선된 재조합 아데노바이러스 및리포좀을 포함하는 조성물 | |
US20040146526A1 (en) | Inhibition of NF-kappaB activation | |
JPH09324000A (ja) | インターロイキン−2受容体を特異的に認識する因子とリボヌクレアーゼとの接合体 | |
AU2022246144A1 (en) | Tmem173 sarna compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |